Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MATERNAL AND INFANT SAFETY AND IMMUNOGENICITY IN A PHASE 3, OPEN-LABEL, RANDOMISED, VACCINE TRIAL OF A TWO-DOSE MPOX VACCINE

Project description

Clinical trial for mpox vaccine

Mpox, a viral disease caused by the monkeypox virus and characterised by flu-like symptoms and a distinctive rash, has recently seen a resurgence outside its traditional endemic regions. Because it can cause severe complications in vulnerable groups such as pregnant women, newborns and young infants, there is a need for targeted public health interventions and vaccine trials. The EU-cofunded PregInPoxVac project is undertaking a clinical trial to assess the safety and immunogenicity of the MVA-BN vaccine in pregnant women, newborns and young infants. The MVA-BN vaccine uses a modified vaccinia Ankara (MVA) virus as its base and has been used to protect against smallpox. The project will also address vaccine hesitancy in a bid to improve uptake in high-risk groups.

Objective

Mpox can cause severe complications in vulnerable groups such as pregnant women and children, necessitating targeted public health interventions and vaccine trials in these populations. Limited data suggest the MVA-BN vaccine is safe for pregnant women and likely poses no risk to breastfed infants, but comprehensive human data are lacking. Trials in endemic areas are crucial for evaluating the vaccine's safety and efficacy in real-world settings.

Vaccine hesitancy, exacerbated by misinformation and distrust in healthcare systems, poses a significant challenge, especially in the Democratic Republic of the Congo. Pregnant women are particularly affected by concerns about vaccine safety, which influences their willingness to vaccinate. Addressing these concerns through targeted communication and community engagement is vital.

A proposed phase 3, randomized trial will assess the safety and immunogenicity of the MVA-BN vaccine in healthy pregnant and postpartum women and in infants/children (6-24 months old). Additionally, a qualitative study on vaccine hesitancy will inform the trial design and implementation, aiming to enhance vaccination uptake in these high-risk groups.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-Mpox

See all projects funded under this call

Coordinator

UNIVERSITEIT ANTWERPEN
Net EU contribution
€ 557 250,00
Address
PRINSSTRAAT 13
2000 Antwerpen
Belgium
Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 557 250,00

Participants (3)